Physician profile
Nathan Frank
NPI 1588812390
$3,509.01
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $52.65 · 2021: $290 · 2022: $2,274 · 2023: $442 · 2024: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $561 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $561.33 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,025.00 | 2022 | |
| Alcon Vision LLC | $304.21 | 2019-2024 | Dailies Total1, Eysuvis, Rocklatan |
| Sun Pharmaceutical Industries INC. | $248.95 | 2019-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $145.63 | 2021-2023 | |
| Abbvie INC. | $107.96 | 2023-2024 | |
| Sight Sciences, INC. | $102.54 | 2022 | |
| Bausch & Lomb Americas INC. | $95.31 | 2023-2024 | Miebo, Vyzulta, Xiidra |
| Dompe US, INC. | $90.88 | 2021-2023 | Oxervate |
| Allergan, INC. | $86.78 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $74.50 | 2019 | |
| Oyster Point Pharma, INC. | $65.62 | 2022-2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $61.11 | 2020-2021 | |
| Maculogix, INC. | $35.60 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $32.41 | 2021 | |
| Mallinckrodt Enterprises LLC | $16.67 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $15.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.